Notably, the combined administration of a GLP-1 analog and fibroblast growth factor 21 (FGF21) has been shown to mitigate inflammation and atherosclerosis by modulating the Akt and ERK1/2 signaling pathways, suggesting potential clinical applications for managing diabetes-related vascular complications [143]. The gene discussed is FGF21; the disease is diabetes mellitus.